biostudies-literatureWei QSGuangdong Provincial Department of Science and TechnologyGuangdong Province Natural Science Fund ProjectNational Natural Science Foundation of China65-73https://www.ebi.ac.uk/biostudies/studies/S-EPMC6718872biostudies-literatureUnknown18<h4>Background/objective</h4>A prospective cohort study aimed to evaluate the clinical efficacy of a specific vasoactive herbal formula, Huo Xue Tong Luo capsule (HXTL capsule), for the treatment of patients with asymptomatic osteonecrosis of femoral head (ONFH).<h4>Methods</h4>We evaluated a clinical trial of 55 patients (59 hips) with asymptomatic ONFH (no joint collapse) evaluated by Steinberg staging system and necrosis range classification criteria. Then, they were given HXTL capsule under specific protocol. Among them, 39 males and 16 females with an average age of 36.4 ± 10.1 years were followed up for an average of 4.38 years during treatment. The aggravation of clinical and imaging results was assessed by initial pain and joint collapse. The clinical and imaging outcomes of these Journal of orthopaedic translationHuo Xue Tong Luo capsule, a vasoactive herbal formula prevents progression of asymptomatic osteonecrosis of femoral head: A prospective study.PMC6718872814736972017A030313698818733272016A02022602881573996Wei QSChen ZQYuan YJHe WHong GJZhang QWfalseHuo Xue Tong Luo capsule, a vasoactive herbal formula prevents progression of asymptomatic osteonecrosis of femoral head: A prospective study.<h4>Background/objective</h4>A prospective cohort study aimed to evaluate the clinical efficacy of a specific vasoactive herbal formula, Huo Xue Tong Luo capsule (HXTL capsule), for the treatment of patients with asymptomatic osteonecrosis of femoral head (ONFH).<h4>Methods</h4>We evaluated a clinical trial of 55 patients (59 hips) with asymptomatic ONFH (no joint collapse) evaluated by Steinberg staging system and necrosis range classification criteria. Then, they were given HXTL capsule under specific protocol. Among them, 39 males and 16 females with an average age of 36.4 ± 10.1 years were followed up for an average of 4.38 years during treatment. The aggravation of clinical and imaging results was assessed by initial pain and joint collapse. The clinical and imaging outcomes of these 2019-01-01T00:00:00Z2019 Jul2025-04-04T07:52:11.524Z2019-09-14T07:04:26ZS-EPMC67188723150830910.1016/j.jot.2018.11.002